Research & Literature

Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience.

Sanchorawala V, Sun F, Quillen K, et al.

Blood 2015; (126(20)):2345-7 doi:10.1182/blood-2015-08-662726.

Risk factors for venous thromboembolism in immunoglobulin light chain amyloidosis.

Bever KM, Masha LI, Sun F, et al.

Haematologica 2016; (101(1)):86-90 doi:10.3324/haematol.2015.133900.

Free light chain testing for the diagnosis, monitoring and prognostication of AL amyloidosis.

Mollee P, Merlini G

Clinical chemistry and laboratory medicine 2016; (54(6)):921-7.

Implementation and evaluation of amyloidosis subtyping by laser-capture microdissection and tandem mass spectrometry.

Mollee P, Boros S, Loo D, et al.

Clinical proteomics 2016; (13()):30 doi:10.1186/s12014-016-9133-x.

Current applications of multiparameter flow cytometry in plasma cell disorders.

Jelinek T, Bezdekova R, Zatopkova M, et al.

Blood cancer journal 2017; (7(10)):e617 doi:10.1038/bcj.2017.90.

Rapid hematologic responses improve outcomes in patients with very advanced (stage IIIb) cardiac immunoglobulin light chain amyloidosis.

Manwani R, Foard D, Mahmood S, et al.

Haematologica 2018; (103(4)):e165-e168 doi:10.3324/haematol.2017.178095.

Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time.

Sidiqi MH, Aljama MA, Buadi FK, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018; (36(13)):1323-1329 doi:10.1200/JCO.2017.76.9554.

Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis.

Abeykoon JP, Zanwar S, Dispenzieri A, et al.

Leukemia 2019; (33(2)):531-536 doi:10.1038/s41375-018-0262-2.

Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis.

Lilleness B, Ruberg FL, Mussinelli R, et al.

Blood 2019; (133(3)):215-223 doi:10.1182/blood-2018-06-858951.

Recent Advances in the Diagnosis, Risk Stratification, and Management of Systemic Light-Chain Amyloidosis.

Vaxman I, Gertz M

Acta haematologica 2019; (141(2)):93-106 doi:10.1159/000495455.

[Free light chains assay: Indications and methods].

Martellosio JP, Leleu X, Roblot P, et al.

La Revue de medecine interne 2019; (40(5)):297-305 doi:10.1016/j.revmed.2019.01.005.

Cardiorenal AL amyloidosis: risk stratification and outcomes based upon cardiac and renal biomarkers.

Rezk T, Lachmann HJ, Fontana M, et al.

British journal of haematology 2019; (186(3)):460-470 doi:10.1111/bjh.15955.

Simple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: prospective study in 206 patients.

Tasaki M, Milani P, Foli A, et al.

Blood 2019; (134(3)):320-323 doi:10.1182/blood.2019000420.

A risk stratification for systemic immunoglobulin light-chain amyloidosis with renal involvement.

Li T, Huang X, Wang Q, et al.

British journal of haematology 2019; (187(4)):459-469 doi:10.1111/bjh.16112.

A 24-year experience of autologous stem cell transplantation for light chain amyloidosis patients in the United Kingdom.

Sharpley FA, Petrie A, Mahmood S, et al.

British journal of haematology 2019; (187(5)):642-652 doi:10.1111/bjh.16143.

The sensitivity and specificity of the routine kidney biopsy immunofluorescence panel are inferior to diagnosing renal immunoglobulin-derived amyloidosis by mass spectrometry.

Gonzalez Suarez ML, Zhang P, Nasr SH, et al.

Kidney international 2019; (96(4)):1005-1009 doi:10.1016/j.kint.2019.05.027.

Immunoelectron microscopy and mass spectrometry for classification of amyloid deposits.

Abildgaard N, Rojek AM, Møller HE, et al.

Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2020; (27(1)):59-66 doi:10.1080/13506129.2019.1688289.

Supportive Care in AL Amyloidosis.

Cibeira MT, Ortiz-Pérez JT, Quintana LF, et al.

Acta haematologica 2020; (143(4)):335-342 doi:10.1159/000506760.

Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment.

Gertz MA

American journal of hematology 2020; (95(7)):848-860 doi:10.1002/ajh.25819.

Massive Hepatomegaly Secondary to Amyloidosis with Normal Liver Chemistries.

Doe-Williams S, Hixson LJ, Pfeiffer DC

Case reports in gastroenterology 2020; (14(2)):271-278 doi:10.1159/000507612.

Confirming the Diagnosis of Amyloidosis.

Wisniowski B, Wechalekar A

Acta haematologica 2020; (143(4)):312-321 doi:10.1159/000508022.

A study from The Mayo Clinic evaluated long-term outcomes of kidney transplantation in patients with immunoglobulin light chain amyloidosis.

Heybeli C, Bentall A, Wen J, et al.

Kidney international 2021; (99(3)):707-715 doi:10.1016/j.kint.2020.06.036.

Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis.

Kastritis E, Fotiou D, Theodorakakou F, et al.

Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2021; (28(1)):3-11 doi:10.1080/13506129.2020.1798224.

Sequential response-driven bortezomib-based therapy followed by autologous stem cell transplant in AL amyloidosis.

Basset M, Milani P, Nuvolone M, et al.

Blood advances 2020; (4(17)):4175-4179 doi:10.1182/bloodadvances.2020002219.

Renal Involvement in Systemic Amyloidosis Caused by Monoclonal Immunoglobulins.

Karam S, Leung N

Hematology/oncology clinics of North America 2020; (34(6)):1069-1079 doi:10.1016/j.hoc.2020.08.002.

Monoclonal Antibody Therapies in Systemic Light-Chain Amyloidosis.

Godara A, Palladini G

Hematology/oncology clinics of North America 2020; (34(6)):1145-1159 doi:10.1016/j.hoc.2020.08.005.

Supportive Care for Patients with Systemic Light Chain Amyloidosis.

Wong SW, Fogaren T

Hematology/oncology clinics of North America 2020; (34(6)):1177-1191 doi:10.1016/j.hoc.2020.08.007.

Race/ethnicity in systemic AL amyloidosis: perspectives on disease and outcome disparities.

Staron A, Connors LH, Zheng L, et al.

Blood cancer journal 2020; (10(11)):118 doi:10.1038/s41408-020-00385-0.

Management of AL amyloidosis in 2020.

Palladini G, Milani P, Merlini G

Blood 2020; (136(23)):2620-2627 doi:10.1182/blood.2020006913.

Extensive amyloid deposits in bone marrow aspirate smears.

Li THS, Wong KF, Wong WS

Clinical case reports 2020; (8(12)):3581-3582 doi:10.1002/ccr3.3236.

Electrocardiographic parameters and prognosis of renal light chain amyloidosis.

Li H, Wang Y, Lan P, et al.

Clinical cardiology 2020; (43(10)):1160-1166 doi:10.1002/clc.23426.

Monoclonal gammopathy of renal significance (MGRS)-related AL amyloidosis complicated by amyloid myopathy: a case report.

Ono E, Ishii A, Higashi Y, et al.

BMC nephrology 2021; (22(1)):74 doi:10.1186/s12882-021-02272-7.

First-line daratumumab shows high efficacy and tolerability even in advanced AL amyloidosis: the real-world experience.

Jeryczynski G, Antlanger M, Duca F, et al.

ESMO open 2021; (6(2)):100065 doi:10.1016/j.esmoop.2021.100065.

Pathophysiology and Therapeutic Approaches to Cardiac Amyloidosis.

Griffin JM, Rosenblum H, Maurer MS

Circulation research 2021; (128(10)):1554-1575 doi:10.1161/CIRCRESAHA.121.318187.

Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.

Kastritis E, Palladini G, Minnema MC, et al.

The New England journal of medicine 2021; (385(1)):46-58 doi:10.1056/NEJMoa2028631.

Case report of amyloid light-chain amyloidosis with periocular cutaneous involvement

Haász C, Kuroli E, Anker P, et al.

Orvosi hetilap 2021; (162(32)):1303-1308 doi:10.1556/650.2021.32137.

Dealing With High-Risk AL Amyloidosis Patients: A Single Hematologic Center Experience.

Riva M, Berno T, Cipriani A, et al.

Clinical lymphoma, myeloma & leukemia 2021; (21(12)):e970-e974 doi:10.1016/j.clml.2021.07.015.

Fixed duration vs. prolonged duration treatment after first line therapy in patients with systemic light chain amyloidosis.

Rivera Duarte A, Reece D, Li X, et al.

Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2022; (29(1)):23-30 doi:10.1080/13506129.2021.1978423.

Screening for hereditary transthyretin amyloidosis in Bulgaria.

Nakov R, Nakov V, Gospodinova M, et al.

Medicine and pharmacy reports 2021; (94(Suppl No 1)):S8-S10 doi:10.15386/mpr-2218.

AL Amyloidosis: Current Chemotherapy and Immune Therapy Treatment Strategies: JACC: CardioOncology State-of-the-Art Review.

Bianchi G, Zhang Y, Comenzo RL

JACC. CardioOncology 2021; (3(4)):467-487 doi:10.1016/j.jaccao.2021.09.003.

Relationship of tumor load parameters before and after autologous stem cell transplantation with clinical prognosis in transplant-eligible patients with multiple myeloma: A retrospective analysis.

Minakata D, Fujiwara SI, Murahashi R, et al.

Leukemia research 2022; (112()):106750 doi:10.1016/j.leukres.2021.106750.

Independent Prognostic Utility of 11C-Pittsburgh Compound B PET in Patients with Light-Chain Cardiac Amyloidosis.

Choi YJ, Koh Y, Lee HJ, et al.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2022; (63(7)):1064-1069 doi:10.2967/jnumed.121.263033.

Proposed Cardiac End Points for Clinical Trials in Immunoglobulin Light Chain Amyloidosis: Report From the Amyloidosis Forum Cardiac Working Group.

Maurer MS, Dunnmon P, Fontana M, et al.

Circulation. Heart failure 2022; (15(6)):e009038 doi:10.1161/CIRCHEARTFAILURE.121.009038.

Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis.

Blair HA

Drugs 2022; (82(6)):683-690 doi:10.1007/s40265-022-01705-3.

The clinical features and outcomes of systemic light chain amyloidosis with hepatic involvement.

Zhao L, Ren G, Guo J, et al.

Annals of medicine 2022; (54(1)):1226-1232 doi:10.1080/07853890.2022.2069281.

Macroglossia as the initial presentation of AL amyloidosis: review and updates in treatment.

Cherico AS, Rizvi A, Jayakrishnan T, Mewawalla P

BMJ case reports 2022; (15(7)) doi:10.1136/bcr-2022-249737.

Amyloidosis of the Heart and Kidney.

Adrogue HE

Methodist DeBakey cardiovascular journal 2022; (18(4)):27-33 doi:10.14797/mdcvj.1150.

Renal amyloidosis: a new time for a complete diagnosis.

Feitosa VA, Neves PDMM, Jorge LB, et al.

Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica 2022; (55()):e12284 doi:10.1590/1414-431X2022e12284.

Diagnostic and Therapeutic Considerations in Concurrent Plasma Cell Dyscrasia and Amyloidosis.

Baljevic M

Qatar medical journal 2022; (2022(3)):44 doi:10.5339/qmj.2022.44.

Untangling Amyloidosis: Recent Advances in Cardiac Amyloidosis.

Kim D, Choi JO, Kim K, et al.

International journal of heart failure 2020; (2(4)):231-239 doi:10.36628/ijhf.2020.0016.

Single Center Experience of Autologous Stem Cell Transplantation in Patients with Systemic Light Chain Amyloidosis in Korea.

Kim HR, Yoon SE, Kim D, et al.

Clinical lymphoma, myeloma & leukemia 2023; (23(2)):97-103 doi:10.1016/j.clml.2022.10.010.

Diagnosis and Treatment of AL Amyloidosis.

Palladini G, Milani P

Drugs 2023; (83(3)):203-216 doi:10.1007/s40265-022-01830-z.

Anxious/Depressive Symptoms Alter the Subjective Perception of Heart Failure Severity in Transthyretin Cardiac Amyloidosis.

Ponti L, Smorti M, Pozza F, et al.

The American journal of cardiology 2023; (192()):1-6 doi:10.1016/j.amjcard.2023.01.007.

Diagnostic and Treatment Strategies for AL Amyloidosis in an Era of Therapeutic Innovation.

Dima D, Mazzoni S, Anwer F, et al.

JCO oncology practice 2023; (19(5)):265-275 doi:10.1200/OP.22.00396.

Prognostic Value of Left Ventricular 18 F-Florbetapir Uptake in Systemic Light-Chain Amyloidosis.

Clerc OF, Datar Y, Cuddy SA, et al.

medRxiv : the preprint server for health sciences 2023; doi:10.1101/2023.09.13.23295520.

Immunoglobulin light chain amyloidosis: 2024 update on diagnosis, prognosis, and treatment.

Gertz MA

American journal of hematology 2024; (99(2)):309-324 doi:10.1002/ajh.27177.

Thrombotic and bleeding complications in patients with AL amyloidosis.

Fotiou D, Theodorakakou F, Spiliopoulou S, et al.

British journal of haematology 2024; (204(5)):1816-1824 doi:10.1111/bjh.19331.

Evaluation of abdominal fat pad aspiration highlighting challenges to interpretation.

Torous VF, Chebib I

Journal of the American Society of Cytopathology 2024; (13(3)):219-226 doi:10.1016/j.jasc.2024.01.003.

AL amyloidosis: Singapore Myeloma Study Group consensus guidelines on diagnosis, treatment and management.

Tan M, Chen Y, Ooi M, et al.

Annals of the Academy of Medicine, Singapore 2023; (52(11)):601-624 doi:10.47102/annals-acadmedsg.2023101.

Healthcare resource utilisation and costs associated with AL amyloidosis: a retrospective matched cohort study.

Shen SP, Hou HA, Huang KC, et al.

Scientific reports 2024; (14(1)):16915 doi:10.1038/s41598-024-65654-5.

Helical superstructures between amyloid and collagen in cardiac fibrils from a patient with AL amyloidosis.

Schulte T, Chaves-Sanjuan A, Speranzini V, et al.

Nature communications 2024; (15(1)):6359 doi:10.1038/s41467-024-50686-2.

Role of Autologous Stem Cell Transplantation in Systemic Light Chain Amyloidosis.

Parmar H, Doucette K, Vesole D

Clinical lymphoma, myeloma & leukemia 2024; (24(11)):770-777 doi:10.1016/j.clml.2024.06.009.

Treatment Approach for Advanced Systemic Light Chain Amyloidosis: A Case Report.

Hachem MAM, Nasreddine GM, Farhat S, et al.

Cureus 2024; (16(8)):e65960 doi:10.7759/cureus.65960.

Warning values of serum total kappa/lambda ratio for M-proteinemia.

Lu J, Zhu Y, Huang H, et al.

BMC immunology 2024; (25(1)):73 doi:10.1186/s12865-024-00664-6.

Early dFLC response by C1D7 predicts complete hematologic response in systemic AL amyloidosis.

Liu Y, Bi J, Dou X, et al.

Annals of hematology 2025; (104(1)):617-625 doi:10.1007/s00277-024-06077-0.

Primary systemic amyloidosis: A brief overview.

Hughes MS, Lentzsch S

Presse medicale (Paris, France : 1983) 2025; (54(1)):104267 doi:10.1016/j.lpm.2024.104267.

Immunoglobulin heavy/light chain assay in the diagnosis, monitoring and follow-up of renal AL amyloidosis patients at different disease stages.

Wang Y, Liu F, Liu Y, et al.

Annals of hematology 2025; (104(4)):2287-2295 doi:10.1007/s00277-025-06345-7.

AL Amyloidosis: Current Treatment and Outcomes.

Locke M, Nieto M

Advances in hematology 2025; (2025()):7280805 doi:10.1155/ah/7280805.

Detection yield of surrogate tissue biopsies across amyloidosis classes: a large-scale analysis of 4,027 patients.

Burke NJ, Mendelson LM, Joshi T, et al.

Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2025; 1-9 doi:10.1080/13506129.2025.2606847.

Kinetics of hematologic response in AL amyloidosis: Insights from clinical and cytogenetic subgroup analysis in the daratumumab era.

Bazarbachi AH, Zanwar S, Hegenbart U, et al.

HemaSphere 2025; (9(12)):e70276 doi:10.1002/hem3.70276.

A Spatial Proteomics Approach to Isolate and Analyze Amyloid Proteins Using Laser Capture Microdissection and Mass Spectrometry.

Aguilan J, Horton M, Pessin JE, Sidoli S

Methods in molecular biology (Clifton, N.J.) 2026; (3015()):121-134 doi:10.1007/978-1-0716-5154-4_10.

Prognostic Impact of Bone Marrow Plasma Cell Percentage in Patients With Systemic Light-Chain Amyloidosis: A Systematic Review and Meta-Analysis.

Nie ZY, Aihemaiti Y, Meng FQ, et al.

European journal of haematology 2026; (116(6)):826-834 doi:10.1111/ejh.70138.

An Australian Amyloidosis Network analysis of Australian patients with immunoglobulin light chain amyloidosis treated with bortezomib-based chemotherapy.

Gibbons A, Chakravorty L, Sidiqi H, et al.

Internal medicine journal 2026; (56(4)):582-588 doi:10.1111/imj.70335.

The cTnI/cTnT Ratio in Myocardial Injury: A Multicohort and Experimental Synthesis.

Zimmermann T, Koechlin L, Walter J, et al.

Journal of the American College of Cardiology 2026; (87(17)):2211-2230 doi:10.1016/j.jacc.2025.12.078.